All In Biotech

Free tool

FAERS Monitor: Vistogard

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208159 or its brand name (Vistogard, Uridine Triacetate). Reports on generic versions are filed under their own applications.

Reports

125

Serious

66

53% of reports

Hospitalization

31

Death reported

30

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • complication associated with device22
  • vomiting22
  • diarrhoea20
  • death13
  • thrombocytopenia13
  • mucosal inflammation12
  • nausea12
  • inappropriate schedule of product administration10
  • off label use10
  • neutropenia9
  • hypokalaemia8
  • asthenia7
  • product dose omission issue7
  • dysphagia6
  • decreased appetite5

Reports by year received

View as table
YearReports
20141
201615
201718
201815
201913
20204
20217
20224
20233
202413
202512
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
complication associated with deviceSignal22255.3174.75,317
mucosal inflammationSignal1277.245.1828
hypokalaemiaSignal829.214.9191
thrombocytopeniaSignal1319.611.7212
neutropeniaSignal911.15.974
dysphagiaSignal610.64.943
inappropriate schedule of product administrationSignal109.35.267
vomitingSignal227.95.4128
diarrhoeaSignal205.23.566
product dose omission issueSignal74.02.013
decreased appetiteSignal53.61.57
astheniaSignal73.11.58
nauseaSignal122.61.510
deathSignal132.51.511
off label use101.91.14

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.